Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s

As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.

We haven't written up this one. CNBC has the full story — the link below goes straight to it.

Also reported by 1 other outlet

Read the original at cnbc.com →

More in Finance & Markets

More from Friday 25 September →